NCT05268952 is a NA clinical trial of Liquid biopsies in Neuroendocrine Tumors, sponsored by University Hospital, Antwerp.

Who is sponsoring NCT05268952?

NCT05268952 is sponsored by University Hospital, Antwerp.

What drugs are being tested in NCT05268952?

Interventions in NCT05268952: Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT).

What condition does NCT05268952 study?

NCT05268952 studies Neuroendocrine Tumors.

Is NCT05268952 still recruiting?

NCT05268952 is currently status unknown. Last updated 7 March 2022.

Last reviewed 2022-03-07 · How we verify

NCT05268952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

Status unknown NA Last updated 7 March 2022

What this trial tests

NA trial testing Liquid biopsies in Neuroendocrine Tumors in 100 participants. Status unknown.

Timeline

27 May 2019

Primary endpoint
27 May 2025

31 December 2025

Quick facts

Lead sponsor	University Hospital, Antwerp
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	27 May 2019
Primary completion	27 May 2025
Estimated completion	31 December 2025
Sites	3 locations across Belgium, Cyprus

Drugs / interventions tested

Liquid biopsies
Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

University Hospital, Antwerp

Who can join

18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine tumours.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.
Mehta D, Rajput K, Jain D, Bajaj A, et al · · 2024 · cited 17× · PMID 39698262 · DOI 10.1021/acsptsci.4c00530
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.
Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, et al · · 2024 · cited 3× · PMID 38529270 · DOI 10.1177/17588359241240316

Verify or expand the search:

Other trials of Liquid biopsies

Trials testing the same drug.

NCT05255133 — A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic · NA · completed

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other University Hospital, Antwerp trials

Trials by the same sponsor.

NCT07455422 — A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurr · NA · not yet recruiting
NCT07020715 — A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis · Phase 2 · not yet recruiting
NCT07443761 — Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. · active not recruiting
NCT06372847 — DISE-HNS Effect Study · NA · recruiting
NCT07189091 — CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05268952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Antwerp
Last refreshed: 7 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing